Barclays Sticks to Its Buy Rating for Thermo Fisher (TMO)

Barclays analyst Luke Sergott maintained a Buy rating on Thermo Fisher today and set a price target of $625.00.

Claim 70% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Sergott covers the Healthcare sector, focusing on stocks such as Twist Bioscience, Agilent, and Charles River Labs. According to TipRanks, Sergott has an average return of -0.2% and a 45.58% success rate on recommended stocks.

In a report released yesterday, TipRanks – Google also reiterated a Buy rating on the stock with a $676.00 price target.

Based on Thermo Fisher’s latest earnings release for the quarter ending September 27, the company reported a quarterly revenue of $11.12 billion and a net profit of $1.62 billion. In comparison, last year the company earned a revenue of $10.6 billion and had a net profit of $1.63 billion

Based on the recent corporate insider activity of 77 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TMO in relation to earlier this year. Last month, Michel Lagarde, the EVP & COO of TMO sold 22,046.00 shares for a total of $12,424,243.76.